Role of CTCF Protein in Regulating Locus Transcription

English version České info

Fragile X syndrome (FXS), the leading cause of inherited intellectual disability, is caused by epigenetic silencing of the FMR1 gene, through expansion and methylation of a CGG triplet repeat (methylated full mutation). An antisense transcript (FMR1-AS1), starting from both promoter and intron 2 of the FMR1 gene, was demonstrated in transcriptionally active alleles, but not in silent FXS alleles. Moreover, a DNA methylation boundary, which is lost in FXS, was recently identified upstream of the FMR1 gene. Several nuclear proteins bind to this region, like the insulator protein CTCF. Here we demonstrate for the first time that rare unmethylated full mutation (UFM) alleles present the same boundary described in wild type (WT) alleles and that CTCF binds to this region, as well as to the FMR1 gene promoter, exon 1 and intron 2 binding sites. Contrariwise, DNA methylation prevents CTCF binding to FXS alleles. Drug-induced CpGs demethylation does not restore this binding. CTCF knock-down experiments clearly established that CTCF does not act as insulator at the active FMR1 locus, despite the presence of a CGG expansion. CTCF depletion induces heterochromatinic histone configuration of the FMR1 locus and results in reduction of FMR1 transcription, which however is not accompanied by spreading of DNA methylation towards the FMR1 promoter. CTCF depletion is also associated with FMR1-AS1 mRNA reduction. Antisense RNA, like sense transcript, is upregulated in UFM and absent in FXS cells and its splicing is correlated to that of the FMR1-mRNA. We conclude that CTCF has a complex role in regulating FMR1 expression, probably through the organization of chromatin loops between sense/antisense transcriptional regulatory regions, as suggested by bioinformatics analysis.

Vyšlo v časopise: Role of CTCF Protein in Regulating Locus Transcription. PLoS Genet 9(7): e32767. doi:10.1371/journal.pgen.1003601
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003601

Souhrn

Zdroje

1. PirozziF, TabolacciE, NeriG (2011) The FRAXopathies: Definition, overview, and update. Am J Med Genet part A 8: 1803–1816.

2. VerkerkAJ, PierettiM, SutcliffeJS, FuYH, KuhlDP, et al. (1991) Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65: 905–914.

3. PierettiM, ZhangFP, FuYH, WarrenST, OostraBA, et al. (1991) Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66: 817–822.

4. TabolacciE, PietrobonoR, MoscatoU, OostraBA, ChiurazziP, et al. (2005) Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments. Eur J Hum Genet 13: 641–648.

5. ZalfaF, GiorgiM, PrimeranoB, MoroA, Di PentaA, et al. (2003) The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell 112: 317–327.

6. SmeetsHJ, SmitsAP, VerheijCE, TheelenJP, WillemsenR, et al. (1995) Normal phenotype in two brothers with a full FMR1 mutation. Hum Mol Genet 11: 331–334.

7. PietrobonoR, TabolacciE, ZalfaF, ZitoI, TerraccianoA, et al. (2005) Molecular dissection of the events leading to inactivation of the FMR1 gene. Hum Mol Genet 14: 267–277.

8. TabolacciE, MoscatoU, ZalfaF, BagniC, ChiurazziP, et al. (2008) Epigenetic analysis reveals a euchromatic configuration in the FMR1 unmethylated full mutations. Eur J Hum Genet 16: 1487–1498.

9. WillemsenR, BontekoeCJ, SeverijnenLA, OostraBA (2002) Timing of the absence of FMR1 expression in full mutation chorionic villi. Hum Genet 110: 601–605.

10. ChiurazziP, PomponiMG, WillemsenR, OostraBA, NeriG (1998) In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum Mol Genet 7: 109–113.

11. PietrobonoR, PomponiMG, TabolacciE, OostraB, ChiurazziP, et al. (2002) Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine. Nucleic Acids Res 30: 3278–3285.

12. EigesR, UrbachA, MalcovM, FrumkinT, SchwartzT, et al. (2007) Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 1: 568–577.

13. NaumannA, HochsteinN, WeberS, FanningE, DoerflerW (2009) A distinct DNA-methylation boundary in the 5′-upstream sequence of the FMR1 promoter binds nuclear proteins and is lost in fragile X syndrome. Am J Hum Genet 85: 606–616.

14. PhillipsJE, CorcesVG (2009) CTCF: master weaver of the genome. Cell 137: 1194–1211.

15. KlenovaEM, NicolasRH, PatersonHF, CarneAF, HeathCM, et al. (1993) CTCF, a conserved nuclear factor required for optimal transcriptional activity of the chicken c-myc gene, is an 11-Zn-finger protein differentially expressed in multiple forms. Mol Cell Biol 13: 7612–7624.

16. OhlssonR, RenkawitzR, LobanenkovV (2001) CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet 17: 520–527.

17. LobanenkovVV, NicolasRH, AdlerVV, PatersonH, KlenovaEM, et al. (1990) A novel sequence specific DNA binding protein which interacts with three regularly spaced direct repeats of the CCCTC-motif in the 5′-flanking sequence of the chicken c-myc gene. Oncogene 5: 1743–1753.

18. FilippovaGN, FagerlieS, KlenovaEM, MyersC, DehnerY, et al. (1996) An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Mol Cell Biol 16: 2802–2813.

19. WallaceJA, FelsenfeldG (2007) We gather together: insulators and genome organization. Curr Opin Genet Dev 17: 400–407.

20. FilippovaGN (2008) Genetics and epigenetics of the multifunctional protein CTCF. Curr Top Dev Biol 80: 337–360.

21. OhlssonR, LobanenkovV, KlenovaE (2010) Does CTCF mediate between nuclear organization and gene expression? Bioessays 32: 37–50.

22. HandokoL, XuH, LiG, NganCY, ChewE, et al. (2011) CTCF-mediated functional chromatin interactome in pluripotent cells. Nat Genet 43: 630–638.

23. BottaM, HaiderS, LeungIX, LioP, MozziconacciJ (2010) Intra- and inter-chromosomal interactions correlate with CTCF binding genome wide. Mol Syst Biol 6: 426–4431.

24. BellAC, FelsenfeldG (2000) Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 405: 482–485.

25. KanduriC, PantV, LoukinovD, PugachevaE, QiCF, et al. (2000) Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive. Curr Biol 10: 853–856.

26. HarkAT, SchoenherrCJ, KatzDJ, IngramRS, LevorseJM, et al. (2000) CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 405: 486–489.

27. WangH, MauranoMT, QuH, VarleyKE, GertzJ, et al. (2012) Widespread plasticity in CTCF occupancy linked to DNA methylation. Genome Res 22: 1680–1688.

28. ChoDH, ThienesCP, MahoneySE, AnalauE, FilippovaGN, et al. (2005) Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol Cell 20: 483–489.

29. ClearyJD, ToméS, López CastelA, PanigrahiGB, FoiryL, et al. (2010) Tissue- and age-specific DNA replication patterns at the CTG/CAG-expanded human myotonic dystrophy type 1 locus. Nat Struct Mol Biol 17: 1079–1087.

30. López CastelA, NakamoriM, ToméS, ChitayatD, GourdonG, et al. (2011) Expanded CTG repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissues. Hum Mol Genet 20: 1–15.

31. SopherBL, LaddPD, PinedaVV, LibbyRT, SunkinSM, et al. (2011) CTCF regulates ataxin-7 expression through promotion of a convergently transcribed, antisense noncoding RNA. Neuron 70: 1071–1084.

32. De BiaseI, ChutakeYK, RindlerPM, BidichandaniSI (2009) Epigenetic silencing in Friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription. PLoS One 4: e7914.

33. LaddPD, SmithLE, RabaiaNA, MooreJM, GeorgesSA, et al. (2007) An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet 16: 3174–3187.

34. BaoL, ZhouM, CuiY (2008) CTCFBSDB: a CTCF-binding site database for characterization of vertebrate genomic insulators. Nucleic Acids Res 36(Database issue): D83–87.

35. DostieJ, DekkerJ (2007) Mapping networks of physical interactions between genomic elements using 5C technology. Nat Protoc 2: 988–1002.

36. WendtKS, YoshidaK, ItohT, BandoM, KochB, et al. (2008) Cohesin mediates transcriptional insulation by CCCTC-binding factor. Nature 451: 796–801.

37. ChernukhinI, ShamsuddinS, KangSY, BergströmR, KwonYW, et al. (2007) CTCF interacts with and recruits the largest subunit of RNA polymerase II to CTCF target sites genome-wide. Mol Cell Biol 27: 1631–1648.

38. ZampieriM, GuastafierroT, CalabreseR, CiccaroneF, BacaliniMG, et al. (2012) ADP-ribose polymers localized on Ctcf-Parp1-Dnmt1 complex prevent methylation of Ctcf target sites. Biochem J 441: 645–652.

39. ChangJW, HsuHS, NiHJ, ChuangCT, HsiungCH, et al. (2010) Distinct epigenetic domains separated by a CTCF bound insulator between the tandem genes, BLU and RASSF1A. PLoS One 5: e12847.

40. WitcherM, EmersonBM (2009) Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Mol Cell 34: 271–284.

41. McGarveyKM, FahrnerJA, GreeneE, MartensJ, JenuweinT, et al. (2006) Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 66: 3541–3549.

42. HuangS, LiX, YusufzaiTM, QiuY, FelsenfeldG (2007) USF1 recruits histone modification complexes and is critical for maintenance of a chromatin barrier. Mol Cell Biol 27: 7991–8002.

43. WangJ, LunyakVV, JordanIK (2012) Genome-wide prediction and analysis of human chromatin boundary elements. Nucleic Acids Res 40: 511–529.

44. KumariD, UsdinK (2001) Interaction of the transcription factors USF1, USF2, and alpha -Pal/Nrf-1 with the FMR1 promoter. Implications for Fragile X mental retardation syndrome. J Biol Chem 276: 4357–4364.

45. TaftRJ, HawkinsPG, MattickJS, MorrisKV (2011) The relationship between transcription initiation RNAs and CCCTC-binding factor (CTCF) localization. Epigenetics Chromatin 4: 1–13.

46. ZhangH, NiuB, HuJF, GeS, WangH, et al. (2011) Interruption of intrachromosomal looping by CCCTC binding factor decoy proteins abrogates genomic imprinting of human insulin-like growth factor II. J Cell Biol 193: 475–487.

47. GheldofN, TabuchiTM, DekkerJ (2006) The active FMR1 promoter is associated with a large domain of altered chromatin conformation with embedded local histone modifications. Proc Natl Acad Sci USA 103: 12463–12468.

48. BellAC, WestAG, FelsenfeldG (1999) The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell 98: 387–396.